Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Desvenlafaxine Succinate

Criteria

Inclusion Criteria:

• Outpatients who have completed double-blind treatment in study 3151A4-327 for fibromyalgia Syndrome with no major protocol violations and no events that would preclude the patient's entry into the long-term open-label study.

• Women of childbearing potential must have a negative serum pregnancy test result at study start.

Exclusion criteria:

• Presence of any new/and or clinically important medical condition that might compromise patient's safety.

• Use of prohibited treatment.

• Meets any of the exclusion criteria listed for study 3151A4-327.